VJHemOnc is committed to improving our service to you

EHA 2019 | CAR-T treatment outcomes: MM real-world data

VJHemOnc is committed to improving our service to you

Yi Lin

With two regularly approved CD19 CAR T-cell treatments, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, speaks on the importance of real-world data. So far, there are comparable side effects in terms of cytokine release syndrome, neurotoxicity, as well as, clinical response. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter